BiotechTube

vigabatrin

ApprovedTerminated
0 watching 0 views this week🔥 Hot
82
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Complex Partial Seizures

Conditions

Complex Partial Seizures

Trial Timeline

Aug 1, 2010 → Dec 1, 2013

NCT ID
NCT01266291

About vigabatrin

vigabatrin is a approved stage product being developed by Lundbeck for Complex Partial Seizures. The current trial status is terminated. This product is registered under clinical trial identifier NCT01266291. Target conditions include Complex Partial Seizures.

Hype Score Breakdown

Clinical
30
Activity
20
Company
7
Novelty
10
Community
12

Clinical Trials (2)

NCT IDPhaseStatus
NCT01413711ApprovedWithdrawn
NCT01266291ApprovedTerminated

Competing Products

20 competing products in Complex Partial Seizures

See all competitors
ProductCompanyStageHype Score
ZonisamideEisaiPhase 3
77
Eslicarbazepine acetate + Eslicarbazepine acetateSumitomo PharmaPhase 3
77
Everolimus (RAD001) + Everolimus PlaceboNovartisPhase 3
77
Zoledronic acid + PlaceboNovartisPhase 2
52
RAD001 + PlaceboNovartisPhase 2
52
RAD001 + Placebo + Antiepileptic drug (1 to 3 only) + open label RAD001 (only used for post-extension phase)NovartisPhase 3
77
everolimusNovartisPhase 3
77
ranolazineGilead SciencesPhase 2
51
clarithromycin, rifabutinPfizerApproved
84
Pregabalin + PregabalinPfizerApproved
84
PregabalinPfizerPre-clinical
22
AzithromycinPfizerApproved
84
Azithromycin + Rifabutin/rifampinPfizerApproved
84
StavudineBristol Myers SquibbPhase 3
76
Zidovudine + DidanosineBristol Myers SquibbPhase 2
51
Haemocomplettan® P + Human albumin (Placebo)CSLPhase 2/3
64
BE1116 + FFPCSLPhase 3
76
CSL730 + PlaceboCSLPhase 1
32
SabrilLundbeckApproved
82
GWP42003-PJazz PharmaceuticalsPhase 3
74

Other Products from Lundbeck

VortioxetineApproved
82
memantine + memantine + placeboApproved
82
escitalopram + escitalopramApproved
82
BrexpiprazoleApproved
82
losartan (drug)Approved
82